Adimmune (TPE:4142) LT-Debt-to-Total-Asset: 0.20 (As of Dec. 2025)

What is Adimmune LT-Debt-to-Total-Asset?

Adimmune TPE:4142 +2.30% 54 LT-Debt-to-Total-Asset is 0.20 as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 54/100 and a GF Value™ of NT$25.53 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Adimmune's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.20.

Adimmune's long-term debt to total assets ratio declined from Dec. 2024 (0.21) to Dec. 2025 (0.20). It may suggest that Adimmune is progressively becoming less dependent on debt to grow their business.

Adimmune (TPE:4142) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Adimmune LT-Debt-to-Total-Asset Related Terms

Adimmune LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Adimmune's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune LT-Debt-to-Total-Asset Chart

Adimmune Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.16

0.23

0.20

0.21

0.20

Adimmune Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.21	0.21	0.20	0.20

54GF Score

Adimmune Corp TPE:4142

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Adimmune LT-Debt-to-Total-Asset Calculation

Adimmune's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1593.825	/	8192.632
	=	0.19

Adimmune's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	1593.825	/	8192.632
	=	0.19

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.20 mean?

Adimmune (TPE:4142) has a LT-Debt-to-Total-Asset of 0.20 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Adimmune and its competitors.

Is Adimmune's LT-Debt-to-Total-Asset too high?

Adimmune's current LT-Debt-to-Total-Asset is 0.20. Overall, Adimmune has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Adimmune's LT-Debt-to-Total-Asset compare to VRTX and REGN?

Adimmune's LT-Debt-to-Total-Asset of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Adimmune and its competitors. Adimmune's current LT-Debt-to-Total-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Adimmune stock overvalued right now?

Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.53, compared to a current price of NT$17.80 — trading 30.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.20. Adimmune's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Adimmune (TPE:4142), the current LT-Debt-to-Total-Asset is 0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.80 is trading 30.3% below its estimated GF Value™ of NT$25.53. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

LT-Debt-to-Total-Asset: 0.20
GF Value™: NT$25.53 vs. price of NT$17.80 (30.3% below fair value)
GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Industry Healthcare Biotechnology

Comparable Companies ROCO:6976 ROCO:6617 ROCO:7832 TPE:1734 ROCO:7729 ROCO:7754 ROCO:4167 ROCO:4162 ROCO:4157 ROCO:6610 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003

Website https://www.adimmune.com.tw

Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.

54GF Score

Get the complete analysis for TPE:4142

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.80

Price

NT$25.53

GF Value

View TPE:4142 Analysis

See LT-Debt-to-Total-Asset data for all stocks →